Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07047690 · ClinicalTrials.gov registry record · Phase 2
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
A Phase 2 study, sponsored by Galderma R&D.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT07047690 is a Phase 2 study that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 162 participants.
The verdict
NCT07047690, a Phase 2 study, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
Interventions
- DRUG Placebo
- DRUG Nemolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2028-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07047690
The ClinicalTrials.gov registry entry for NCT07047690 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07047690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07047690 about?
NCT07047690 is a clinical study titled "A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis". The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
What is the current status of trial NCT07047690?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2026-02-20. Estimated completion is 2028-07-23.
What interventions are being tested in trial NCT07047690?
The interventions under investigation include: Placebo (DRUG), Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT07047690?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.